Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  lenvatinib mesylate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-303, NCT01321554
Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-J081-202, NCT00946153
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-702, NCT01133977
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-205, NCT01136733
Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-201, NCT00784303
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-204, NCT01111461
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-206, NCT01136967
A Study of E7080 in Subjects With Advanced Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-J081-208, NCT01728623
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-A001-102, NCT00121680
An Open Label Phase I Dose Escalation Study Of E7080
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-E044-101, NCT00121719
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-J081-103, NCT00280397
E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-J081-110, NCT00832819
A Study of E7080 in Subjects With Solid Tumor
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 45
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-J081-105, NCT01268293
Start Over